An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
Author:
Affiliation:
1. GenentechSouth San FranciscoCalifornia
2. Everest Clinical Research Services, TorontoOntarioCanada
3. Columbia UniversityNew YorkNew York
4. University of GlasgowGlasgowUK
5. RocheNutleyNew Jersey
Publisher
Wiley
Subject
Immunology,Rheumatology,Immunology and Allergy
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.38920
Reference40 articles.
1. Patterns of cardiovascular risk in rheumatoid arthritis
2. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE
3. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?
4. Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis
5. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report;Circulation,2002
Cited by 94 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients;Seminars in Arthritis and Rheumatism;2024-10
2. Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy;Frontiers in Immunology;2024-06-24
3. Dynamics of modified cardiovascular risk factors in patients with rheumatoid arthritis on the background of 5-year therapy with an interleukin 6 receptor inhibitor;Rheumatology Science and Practice;2024-03-01
4. Effect of a 12-week high-intensity exercise intervention: a comparison of cardiac exercise adaptations during biological disease-modifying antirheumatic drug treatment (TNF inhibitors vs IL-6 signalling inhibitors) in patients with rheumatoid arthritis – study protocol for a randomised controlled trial;BMJ Open;2023-05
5. JAK-STAT signaling as an ARDS therapeutic target: Status and future trends;Biochemical Pharmacology;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3